Search
                    Celiac Disease Clinical Trials
A listing of 15  Celiac Disease  clinical trials  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            1 - 12 of 15
        
                There are currently 15 active clinical trials seeking participants for Celiac Disease research studies. The states with the highest number of trials for Celiac Disease participants are California, Florida, Texas and Massachusetts.
            
                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    
                
                                    Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
                                
            
            
        Recruiting
                            
            
                The unhide® Project is a non-interventional, longitudinal research study designed to establish a secure data repository of demographic, health, and lifestyle information from individuals with brain inflammation and related neuroinflammatory conditions. Participants in the United States aged 2 years and older will provide self-reported health data, biometrics, and symptom diaries through the MyDataHelps™ app (branded as unhide® for this study). The goal is to create comprehensive longitudinal pro...  Read More             
        
        
    Gender:
                ALL
            Ages:
                2 years and above
            Trial Updated:
                08/18/2025
            
            Locations: Brain Inflammation Collaborative, Delafield, Wisconsin         
        
        
            Conditions: ME/CFS, Post-Acute COVID-19 Syndrome, Rheumatic Arthritis, Juvenile Rheumatoid Arthritis (JRA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Autoimmune Encephalitis, Bipolar Disorder (BPD), Celiac Disease, Celiac Disease in Children, Chronic Lyme Disease, Post-treatment Lyme Disease Syndrome, Crohn's Disease, Dysautonomia, Anorexia Nervosa, Bulimia Nervosa, ARFID, Avoidant / Restrictive Food Intake Disorder, Ehlers Danlos Syndrome, Endometriosis, Fibromyalgia (FM), Long COVID, Lupus, Major Depression, Migraines, Mast Cell Activation Syndrome, Multiple Sclerosis, Myalgic Encephalomyelitis (ME), Myasthenia Gravis, Generalized, Myasthenia Gravis in Children, Narcolepsy, Obsessive Compulsive Disorder (OCD), PANDAS, Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), POTS - Postural Orthostatic Tachycardia Syndrome, General Anxiety Disorder, Social Anxiety Disorder, PTSD - Post Traumatic Stress Disorder, Psoriasis, Traumatic Brain Injury, Tourette's Syndrome, Inflammatory Bowel Disease (IBD), Autoimmune Diseases, Neurological Diseases or Conditions, Psychiatric Disorder, Sjogren's Syndrome, Ulcerative Colitis and Crohn's Disease
        
            
        
    
                
                                    A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease
                                
            
            
        Recruiting
                            
            
                This is a Phase 2a/b, randomized, double-blind, placebo-controlled, parallel-group, 6-arm study to evaluate the efficacy and safety of amlitelimab in adult participants with non-responsive celiac disease (NRCD) who are on a gluten free diet (GFD) with and without simulated inadvertent gluten exposure (SIGE).
The primary purpose of this study is to demonstrate the efficacy of subcutaneous (SC) amlitelimab in male and female participants (aged 18 to 75 years, inclusive) with NRCD. The study will...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                08/14/2025
            
            Locations: FOMAT Medical Research - inSite Digestive Health Care - Arcadia- Site Number : 8400052, Arcadia, California  +110 locations         
        
        
            Conditions: Coeliac Disease, Celiac Disease
        
            
        
    
                
                                    A First-in-human Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease
                                
            
            
        Recruiting
                            
            
                The goal of this clinical trial is to learn about the safety of a single dose of HB-2121 in adults. It will also look at how the body processes the drug. The main questions it aims to answer are:
* What side effects do participants have after receiving HB-2121?
* How much HB-2121 is in the blood over time?
Researchers will follow participants for 30 days after receiving HB-2121 to understand how the drug behaves in the body and how safe it is.
Participants will:
* Receive one oral dose of HB...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/17/2025
            
            Locations: Stanford University, Stanford, California         
        
        
            Conditions: Celiac Disease, Healthy
        
            
        
    
                
                                    Gluten Technology and Education for Celiac Health
                                
            
            
        Recruiting
                            
            
                The investigators propose to plan for a multi-center randomized controlled trial (M-RCT) to test the effectiveness of novel gluten detection technologies as an adjunct to telemedicine to manage celiac disease in newly diagnosed adults. If successful, the proposed intervention will improve mucosal recovery, promote a shift in current practice of celiac disease management toward long-term monitoring, and represent a significant step toward reducing the severe physical and psychological consequence...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                06/25/2025
            
            Locations: University of Chicago Medical Center, Chicago, Illinois  +3 locations         
        
        
            Conditions: Celiac Disease
        
            
        
    
                
                                    A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease
                                
            
            
        Recruiting
                            
            
                The primary efficacy objective of the trial is to assess the ability of TEV-53408 to attenuate gluten-induced enteropathy in adults with celiac disease.
The primary safety objective of the trial is to assess the safety of TEV-53408 in adults with celiac disease.
A secondary objective is to further assess the efficacy of TEV-53408 in adults with celiac disease.
The expected trial duration per participant is approximately 86 weeks.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 64 years
            Trial Updated:
                06/25/2025
            
            Locations: Teva Investigational Site 12131, Colorado Springs, Colorado  +11 locations         
        
        
            Conditions: Celiac Disease
        
            
        
    
                
                                    Immune Responses to Gluten
                                
            
            
        Recruiting
                            
            
                This is a study of immune responses after eating gluten powder in people with celiac disease and healthy controls.             
        
        
    Gender:
                ALL
            Ages:
                Between 2 years and 101 years
            Trial Updated:
                04/18/2025
            
            Locations: Children's Hospital Colorado, Aurora, Colorado  +1 locations         
        
        
            Conditions: Celiac Disease, Malabsorption Syndromes, Digestive System Disease, Intestinal Disease, Gastrointestinal Diseases, Gluten Sensitivity, Celiac Disease in Children
        
            
        
    
                
                                    Accessing Care, Clinical Trials and Screening for Underserved Children and Adults With Type 1 Diabetes (ACCESS-T1D)
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to identify people with T1D or celiac disease (CD) early in the course of their disease and to improve the methods of screening for these diseases.             
        
        
    Gender:
                ALL
            Ages:
                2 years and above
            Trial Updated:
                04/02/2025
            
            Locations: AdventHealth Translational Research Institute, Orlando, Florida         
        
        
            Conditions: Type 1 Diabetes, Celiac Disease
        
            
        
    
                
                                    VTP-1000 in Adults with Celiac Disease
                                
            
            
        Recruiting
                            
            
                GLU001 is a first-in-human clinical trial to assess the safety and tolerability of VTP-1000 for adults with celiac disease. This trial will assess VTP-1000 at various dose levels compared to placebo in a single ascending dose (SAD) and multiple ascending dose (MAD) format. Participants will be followed for a short period of time to assess the impact of VTP-1000 on their immune system (Adverse events, reactions in the blood, and physical exam differences). Participants enrolled in the MAD portion...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 65 years
            Trial Updated:
                03/18/2025
            
            Locations: Parexel EPCU LA, Los Angeles, California  +7 locations         
        
        
            Conditions: Celiac Disease
        
            
        
    
                
                                    Celiac Disease Genomic Environmental Microbiome and Metabolomic Study
                                
            
            
        Recruiting
                            
            
                Celiac disease (CD) is a complex disease caused by eating gluten, a protein contained in wheat, rye, and barley. It is well known that many factors contribute to the development of CD, including the genes that you have and the foods that you eat. In the CDGEMM study, we will consider as many of these factors as possible and study how they each contribute to disease development. If the investigators find that any one factor, or combination of factors, increases the risk of developing CD, we will...  Read More             
        
        
    Gender:
                ALL
            Ages:
                6 months and below
            Trial Updated:
                02/18/2025
            
            Locations: MassGeneral Hospital for Children, Boston, Massachusetts  +1 locations         
        
        
            Conditions: Celiac Disease
        
            
        
    
                
                                    Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission
                                
            
            
        Recruiting
                            
            
                Subjects include: aged 18 to 75 years, inclusive, have biopsy-confirmed disease that is clinically inactive as determined by negative celiac disease (CeD) serology and histology (determined via endoscopy at time of screening), have followed a gluten-free diet (GFD) for ≥6 months as reported by the subject, and be human leukocyte antigen (HLA)-DQ2.5 and/or HLA-DQ8 positive.
Study involves the following randomized intervention; 10g gluten + 200mg of Ritlecitinib or placebo             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                02/18/2025
            
            Locations: Massachusetts General Hospital, Boston, Massachusetts         
        
        
            Conditions: Celiac Disease
        
            
        
    
                
                                    Tissue Destruction and Healing in Celiac Disease
                                
            
            
        Recruiting
                            
            
                The purpose of this clinical study is to learn more about celiac disease pathogenesis and clinical symptoms. In particular, this study will examine the interactions between biological factors such as, intestinal epithelial cells, microbiota, immune system, genetics, and gluten and their effect on celiac disease clinical symptoms, and severity of tissue destruction and its ability to heal in individuals with celiac disease. Information collected in the study will help researchers to generate bett...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                01/10/2025
            
            Locations: California Institute of Technology, Pasadena, California  +2 locations         
        
        
            Conditions: Celiac Disease
        
            
        
    
                
                                    Urine Metabolites in the Diagnosis of Disease
                                
            
            
        Recruiting
                            
            
                The goal of this observational study is to validate a non-invasive, urine-based diagnostic technology for the detection and differentiation of various gastrointestinal (GI) diseases.
This research study intends to enroll participants across a range of demographics and GI disease states including colorectal cancer, small intestinal bacterial overgrowth (SIBO), Crohn\'s disease, and Celiac disease, collect urine samples and clinical data, and use artificial intelligence and machine learning t...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                12/11/2024
            
            Locations: Unio Health Partners (Gastroenterology), Encinitas, California  +3 locations         
        
        
            Conditions: Colorectal Cancer, Small Intestinal Bacterial Overgrowth Syndrome (SIBO), Crohn Disease, Celiac Disease
        
            
        
    1 - 12 of 15
            